Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma
DOC1021(dubodencel)用于胶质母细胞瘤辅助免疫治疗的I期临床研究
期刊:
影响因子:
doi:10.64898/2026.03.28.26349013
Georges, J F; Clay, C; Amin, S; Goralczyk, A; Mossop, C; Bilbao, C J; Valeri, A; Ifrach, J; Zaher, M; Colman, L; Kohler, L; Schumann, E H; Vu, M; Burns, B A; Trivedi, A; Liu, W; Namekar, M; Hofferek, C J; Ernste, K J; Bisht, N; Vazquez-Perez, J; Oyewole-Said, D; Amanya, S B; Rodriguez, V; Kraushaar, D C; Okoebor, D; Bellayr, I; Hartenbach, J; Halpert, M M; Duus, E M; Aguilar, L K; Hsu, S H; Zhu, J-J; Zvavanjanja, R C; Bai, Y; Kang, S W; Jang, H-J; Lee, H S; Garg, R; Esquenazi, Y; Tandon, N; Turtz, A; Konduri, V; Decker, W K